Drug Trial Radar · NCT06595186
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Oct 31, 2022
Primary completion
Aug 16, 2026
Study completion Dec 16, 2026
Sponsor
- Lead sponsor
- JenKem Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was designed to evaluate the safety, tolerability, efficacy and pharmacokinetics of JK-1201I combined with adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and concomitant radio-chemotherapy.
Conditions
- Glioblastoma Multiforme (GBM)
Interventions
JK-1201IDrug
JK-1201I will be administered.
Temozolomide (TMZ)Drug
Temozolomide will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Grade of Participants with Adverse Events or Serious Adverse EventsTime frame: From the date of first dose to the end of safety follow-up; Up to 12 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.